MBX 5765

What is MBX 5765?

MBX 5765 is MBX Biosciences' investigational prodrug version of amycretin — a single-peptide dual amylin and GLP-1 receptor agonist originally in development by Novo Nordisk. Amycretin combines amylin agonism (via the calcitonin receptor / RAMP1-3 complexes) and GLP-1 receptor agonism in a single molecule, producing additive satiety, gastric-emptying, and glucagon-suppression effects. The MBX 5765 prodrug engineering aims to produce extended pharmacokinetics relative to the parent amycretin, potentially supporting less-frequent dosing intervals. As of mid-2026, MBX 5765 is in Phase 1 with limited public data; the molecule is positioned within MBX's broader portfolio of GLP-1-axis peptide engineering.

What MBX 5765 Is Investigated For

MBX 5765 is an early-stage prodrug version of amycretin, designed to provide extended pharmacokinetics. The mechanism (amylin plus GLP-1 dual receptor agonism) is biologically well-characterized: amylin agonism complements GLP-1 agonism through largely independent central appetite circuits, producing additive satiety effects beyond either pathway alone. The CagriSema (cagrilintide + semaglutide) precedent suggests dual amylin/GLP-1 activation can produce 22.7% weight loss at 68 weeks. The honest caveats: MBX 5765 is Phase 1, public data is limited, and the competitive landscape is increasingly dense — amycretin from Novo Nordisk, eloralintide, petrelintide, and combination amylin-GLP-1 strategies are all in active development.

History & Discovery

Amycretin was originally developed by Novo Nordisk as a single-peptide amylin and GLP-1 dual agonist alternative to combination cagrilintide + semaglutide. MBX 5765 is MBX Biosciences' prodrug engineering applied to the amycretin scaffold, producing an extended-action variant. Development is at Phase 1 stage as of mid-2026.

How It Works

Two appetite hormones (amylin and GLP-1) work together to help you feel full and eat less. MBX 5765 is a slow-release version of amycretin — a single peptide that activates both receptors at once, designed to give a longer-lasting effect from each dose.

Amycretin (and by extension MBX 5765) binds both the amylin receptor complex (calcitonin receptor with RAMP1-3) and the GLP-1 receptor. Amylin agonism activates the area postrema in the brainstem and downstream central anorectic circuits, slows gastric emptying, and suppresses postprandial glucagon. GLP-1 agonism activates hypothalamic appetite-regulating circuits, slows gastric emptying through a partially overlapping mechanism, and enhances glucose-dependent insulin secretion. The combined dual receptor agonism produces additive effects — amylin and GLP-1 act on distinct but complementary central appetite circuits. The MBX 5765 prodrug strategy adds engineered chemistry to the amycretin backbone, intended to produce extended pharmacokinetic profile while preserving the dual receptor engagement.

Evidence Snapshot

Research Gaps & Open Questions

What the current literature has not yet settled about MBX 5765:

• 01Phase 1 efficacy and safety — pending.
• 02Comparison versus parent amycretin and versus CagriSema.
• 03Long-term safety.

Forms & Administration

Subcutaneous injection — extended interval anticipated.

Dosing & Protocols

The ranges below reflect protocols commonly discussed in the literature and by clinicians — not a prescription. Actual dosing for any individual should be determined by a qualified healthcare provider who knows the patient.

Investigational.

Timeline of Effects

Common Questions

Who MBX 5765 Is NOT For

Drug & Supplement Interactions

Class-level GLP-1 and amylin interaction considerations apply — slowed gastric emptying may affect concurrent oral drug absorption.

Safety Profile

Legal Status

Regulatory status changes over time. Verify current local rules with a qualified professional.

Myths & Misconceptions